Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

NCT02212379 ·Status: COMPLETED ·Phase: PHASE2

RAltegravir Switch STudy: Effects on Endothelial Recovery

NCT01453933 ·Status: UNKNOWN ·Phase: PHASE4

Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine

NCT02284035 ·Status: COMPLETED ·Phase: PHASE3

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879 ·Status: COMPLETED ·Phase: NA

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

NCT01225705 ·Status: WITHDRAWN ·Phase: PHASE4

Evaluation of Low-dose Darunavir in a Switch Study

NCT02671383 ·Status: COMPLETED ·Phase: PHASE3

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227 ·Status: COMPLETED ·Phase: PHASE4

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

NCT00838162 ·Status: COMPLETED ·Phase: PHASE2

Etravirine Plus 2 Analogs in HIV-infected Patients

NCT01437241 ·Status: COMPLETED

Lopinavir Capsules to Kaletra or Invirase Tablets

NCT00438152 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients

NCT00647244 ·Status: COMPLETED ·Phase: PHASE4

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

NCT00234975 ·Status: COMPLETED ·Phase: PHASE4

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824 ·Status: COMPLETED ·Phase: PHASE3

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

NCT00677300 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

NCT01105611 ·Status: UNKNOWN ·Phase: PHASE4

A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC

NCT00002046 ·Status: COMPLETED ·Phase: NA

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970 ·Status: TERMINATED ·Phase: PHASE4

Switch to Maraviroc + Integrase Inhibitor

NCT01896921 ·Status: COMPLETED ·Phase: PHASE3

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

NCT04012931 ·Status: COMPLETED ·Phase: PHASE2

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

NCT03311945 ·Status: COMPLETED ·Phase: PHASE3

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

NCT00038532 ·Status: COMPLETED ·Phase: PHASE2

Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction

NCT04281459 ·Status: COMPLETED ·Phase: NA

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

NCT02581202 ·Status: COMPLETED

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

NCT00752037 ·Status: COMPLETED ·Phase: PHASE4

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3